After obtaining the Central Drugs Standard Control Organization’s (CDSCO) marketing authorization earlier in the year, Sanofi India Limited launched its new diabetic medication, Soliqua®. Adults with obesity and type 2 diabetes mellitus who are not well controlled on oral or injectable medications may benefit from using Soliqua® as a treatment to improve glycemic control as an addition to diet and exercise.

Having type 2 diabetes can make daily living difficult and complex. Many patients who are on various drugs struggle to maintain their blood sugar levels and must also deal with weight gain, hypoglycemia, and repeated injection pricks. Helping them achieve and maintain ideal glycemic (blood sugar) control is urgently needed to allay these concerns. By providing patients with a simple, once-daily injection that may easily fit into their lifestyle and help them overcome the difficulty of managing their diabetes, Soliqua® helps patients achieve sustained blood-sugar control throughout the day.

A once-daily injectable combination medication called Soliqua® contains lixisenatide, an agonist of the GLP-1 receptor, and insulin glargine, 100 Units/ml. With the current low therapeutic cost of INR 1850 per pen, patients with type 2 diabetes mellitus can now have wider access to this worldwide invention.

For more details visit: www.sanofi.in 

Priyanka Dutta